BiotechTube

TURALIO™

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatotoxicity

Conditions

Hepatotoxicity, Tenosynovial Giant Cell Tumor

Trial Timeline

Jan 7, 2021 → Jun 1, 2036

NCT ID
NCT04635111

About TURALIO™

TURALIO™ is a pre-clinical stage product being developed by Daiichi Sankyo for Hepatotoxicity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04635111. Target conditions include Hepatotoxicity, Tenosynovial Giant Cell Tumor.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT04635111Pre-clinicalRecruiting

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85